Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Sponsor: National Cancer Institute (NCI)
A PHASE2/PHASE3 clinical study on CCND1 Gene Amplification and CCND2 Gene Amplification, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 13 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2021 — May 2023 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Feb 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Aug 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .